9 Month 28 Day, Keyuan Pharmaceutical (Stock Code: 301281.SZ ) Its wholly-owned subsidiary, Linuo Pharmaceutical's Injectable Products Project AI+ The groundbreaking ceremony for the intelligent computing power factory was grandly held in Jinan. Over a hundred guests attended the event, including representatives from the Jinan Municipal Market Supervision Administration, the Municipal Bureau of Industry and Information Technology, the Municipal Bureau of Commerce, the Municipal Bureau of Science and Technology, the Licheng District Government, as well as local subdistrict offices. Also present were pharmaceutical industry experts and scholars, upstream and downstream partner companies, financial institutions, and members of the media community, all coming together to witness the occasion at Keway Pharmaceutical. & Lilun Pharmaceutical Achieves a Major Breakthrough in Intelligent Manufacturing of Injectable Pharmaceuticals.

It is reported that the project has a total floor area of approximately 46000 Square meters, including the quality inspection and R&D building, a high-end injectable drug production facility, and an integrated intelligent automated warehouse. The project's production and quality management systems are designed in accordance with national standards. GMP , United States FDA The European Union GMP The facility is a state-of-the-art, intelligent manufacturing plant for injectables, integrating smart production, lean manufacturing, green production, and safe operations. It stands as a key project for Shandong Province’s green, low-carbon, and high-quality development, as well as a flagship initiative for enterprise technology upgrades and a major industrial research project aimed at transforming Shandong’s traditional growth drivers into innovative, sustainable ones.

Yu Bingji, Deputy Secretary of the Licheng District Committee and District Mayor

Luo Leiming, Chief Physician of the Cardiology Department at Beijing 301 Hospital and Expert Consultant for Health Care Services of the Central Military Commission

Pan Guangcheng, Senior Chairman of the China Association of Chemical Pharmaceutical Industry

Gao Chunpo, Chairman and President of Keyuan Pharmaceutical

Ren Guangqiang, Executive Vice President of Keyuan Pharmaceutical

Li Hongfu, Chairman of Linuo Pharmaceutical

Lino Pharmaceutical President Huang Fangsheng

During the ceremony, Yu Bingji, Deputy Secretary of the Licheng District Committee and District Mayor; Luo Leiming, Chief Physician of the Cardiology Department at Beijing 301 Hospital and a senior expert consultant for health care services under the Central Military Commission; Pan Guangcheng, Senior Chairman of the China Association of Chemical Pharmaceutical Industry; and Gao Chunpo, Chairman and President of Keyuan Pharmaceutical, delivered speeches in succession. This powerful convergence of government endorsement, clinical expertise, industry leadership, and collaborative partnerships has provided an unprecedented level of height, depth, and breadth for the future development of this digital-intelligent factory, firmly establishing a solid foundation for the project's ambitious, high-starting-point completion.

The event also featured the unveiling and final touch ceremony for the Kirin IP characters created by Keyuan Pharmaceutical & Linuo Pharmaceutical, as well as a strategic signing ceremony between Keyuan Pharmaceutical, Linuo Pharmaceutical, and their various upstream and downstream partners. 。

Keyuan Pharmaceutical is a leading enterprise in China's niche segment of chemical APIs. Its subsidiary, Linuo Pharmaceutical, focuses on finished dosage forms, leveraging the synergistic advantages of integrated API and formulation production. As a result, the company has built strong capabilities and competitive edge in areas such as antidiabetic drugs, cardiovascular medications, and central nervous system therapies. For many years, the company has been dedicated to oral solid dosage forms, and the completion of this project marks a significant milestone for Keyuan Pharmaceutical. & Linuo Pharmaceutical Achieving the leap from oral solid dosage forms to the high-tech, barrier-intensive field of injectables, a new industrial ecosystem is rapidly taking shape—characterized by the coexistence of multiple dosage forms and the symbiotic collaboration of diverse players.

Highlight Reveal: AI+ The Cutting-Edge Capabilities of a Computing-Power Intelligent Factory

1 Smart Park: Green, Low-Carbon, and Intelligent Operations

Leveraging core technologies such as 4K ultra-high-definition monitoring, 5G high-speed transmission, and AI-powered intelligent analysis, the factory has built a smart park platform that integrates intelligent manufacturing, energy management, security, and environmental protection. This system enables real-time monitoring and dynamic optimization of energy consumption—such as water, electricity, and gas—enabling precise carbon footprint management and significant energy savings. At the same time, it features advanced smart early-warning capabilities for safety risks and pollution emissions, ensuring comprehensive protection of park operations and ecological compliance. Ultimately, the platform helps create a modern pharmaceutical industrial park that is highly efficient, resource-intensive, environmentally friendly, low-carbon, and seamlessly integrated with human-machine collaboration.

2 AI-powered digital twins redefine new standards for sterile injectable production.

The production system integrates cutting-edge global pharmaceutical equipment and digital innovation technologies, establishing an intelligent manufacturing framework that covers the entire production process. Plans are already underway to build two production lines: one for lyophilized powder injections and another for BFS (Blow-Fill-Seal) products.

The lyophilized powder injection production line focuses on non-final sterilization injectables, covering both lyophilized powder vials and water injections in glass ampoules; the BFS production line specializes in final sterilization water injections, primarily producing plastic ampoule formulations.

Both production lines utilize digital twin technology, showcasing a highly automated and intelligent manufacturing philosophy. Through technologies such as unmanned material handling, visual inspection, and real-time monitoring, efficiency and product quality consistency have been dramatically enhanced, while significantly reducing the physical workload on personnel.

3 • Smart Laboratory Sets a New Benchmark for Digital Transformation in the Pharmaceutical Quality Inspection Field

The Smart Lab, built around the core principles of "end-to-end visualization, standardized systemization, operational automation, data-driven informatization, and intelligent decision-making," has established a groundbreaking, unmanned quality inspection ecosystem that challenges traditional approaches.

     The laboratory is equipped with an AI-based central control system and a cluster of intelligent robots, enabling fully automated operation across the entire chain—from sample preparation and instrument analysis to data interpretation. Under non-human intervention, it can perform continuous 24/7 testing, boasting highly automated processes and unmanned operation capabilities. The entire experimental process remains clearly visible, ensuring data accuracy and traceability. This approach shifts quality control from "post-event detection" to "proactive prevention," setting a new benchmark for digital transformation in the pharmaceutical quality inspection field.

4 Smart warehousing, intelligent scheduling—pioneering a new paradigm for pharmaceutical warehousing and logistics.

The four-way automated warehouse is equipped with a "smart brain." The WMS system manages the entire lifecycle of materials and finished products, ensuring real-time, zero-error synchronization of inventory data. Meanwhile, the WCS system acts as the "nervous center," seamlessly coordinating every stage of the operation. In the pre-warehouse area, automated loading and unloading robots work in tandem with rail-based transport systems to efficiently handle tasks such as weighing, labeling, and palletizing—entirely automating the process. Inside the production workshop, elevators connect directly to the rail network, enabling finished goods to move "seamlessly" and uninterrupted straight into the warehouse area. Additionally, the pre-warehouse features various types of collaborative AGV robots, achieving inbound and outbound precision down to the millimeter level. This fully unmanned, intelligent operation, backed by cutting-edge warehousing technology, is empowering the pharmaceutical supply chain to accelerate and thrive!

5 • End-to-end value chain development, seamlessly integrating closed-loop management across all business processes

Through information technology initiatives, this project leverages AI to empower the company’s end-to-end operations, building an integrated value chain system that spans from innovative R&D and procurement supply to intelligent production scheduling, lean manufacturing, order fulfillment, marketing, and product services. This approach achieves seamless data integration and intelligent collaboration across all business processes, ensuring data integrity and full traceability, while also enabling comprehensive digital closed-loop management to significantly enhance operational efficiency and accelerate market responsiveness.

6 — Computing power centers interconnected across multiple regions, fostering a new industrial data ecosystem.

The completion of this digital and intelligent factory marks the official integration of the interconnected computing network linking Keyuan Pharmaceutical and Linuo Pharmaceutical across multiple locations. This network features a centralized architecture centered around the Jinan Computing Center, complemented by distributed storage systems at each production site and secure, off-site backup solutions. Moving forward, the Computing Center will seamlessly connect with Beijing’s pharmaceutical R&D database and Hainan’s GSP company’s marketing database, enabling efficient collection, cleansing, analysis, and consolidation of comprehensive data spanning R&D, production, quality control, sales, distribution, and market feedback. Ultimately, this will facilitate the creation of a dedicated computing database, driving the company’s transformative shift from traditional product manufacturing to a new, digitally and information-driven model of smart pharmaceutical innovation.

7 • Building an international system and aligning with the global pharmaceutical market

The project’s production and quality systems have been rigorously established in accordance with international standards such as China’s National GMP, the U.S. FDA, and EU GMP. The facility has comprehensively adopted cutting-edge international technologies, including advanced isolator systems, sterile filling production lines, and real-time monitoring technologies. By systematically implementing the cGMP principles, the factory will achieve a high level of compliance in both its production environment and operational processes, significantly enhancing the international recognition of product quality and strengthening its ability to gain market access. This robust quality compliance framework lays a solid foundation for future global expansion, particularly enabling seamless entry into premium markets in Europe and North America.

As a key strategic move in the upgrade of Keyuan Pharmaceutical and Linuo Pharmaceutical, the completion of this digital and intelligent factory will further enrich the company’s portfolio of high-end pharmaceutical formulations, helping it to capitalize on its early-mover advantage in digital and intelligent transformation, and continuously strengthen its core market competitiveness and influence.

In the future, Keyuan Pharmaceutical and Linuo Pharmaceutical will continue to uphold our core values of "long-termism, product-centricity, and altruism," leveraging technological innovation as our driving force. We will persistently explore new pathways for digital and intelligent pharmaceutical development, helping China's pharmaceutical industry rise to greater heights in global competition—and contributing our wisdom and strength toward the realization of the "Healthy China" strategic vision!